Goldman Sachs Group Inc Sarepta Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 301,021 shares of SRPT stock, worth $33.4 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
301,021
Previous 439,577
31.52%
Holding current value
$33.4 Million
Previous $69.5 Million
45.87%
% of portfolio
0.01%
Previous 0.01%
Shares
19 transactions
Others Institutions Holding SRPT
# of Institutions
531Shares Held
84.5MCall Options Held
2.06MPut Options Held
1.52M-
Black Rock Inc. New York, NY10.3MShares$1.14 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.97MShares$994 Million0.02% of portfolio
-
Capital International Investors Los Angeles, CA6.26MShares$694 Million0.16% of portfolio
-
Janus Henderson Group PLC London, X04.36MShares$483 Million0.29% of portfolio
-
State Street Corp Boston, MA4.27MShares$473 Million0.02% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $9.71B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...